We Claim:

1. An isolated monoclonal antibody or antigen binding fragment thereof that:

a) specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin;

b) specifically binds to Kallidin or des-Arg_{10}-Kallidin with a KD of less than $1x10^{-10}$ M;

c) specifically binds to Kallidin or des-Arg_{10}-Kallidin with a K_{off} of less than $1x10^{4}$ s^{-1}; and/or

d) specifically binds to Kallidin or des-Arg_{10}-Kallidin and inhibits binding to the bradykinin B1 receptor.

2. The antibody or antigen binding fragment thereof of any of the preceding claims that binds to the N-terminal Lysine residue of Kallidin or des-Arg_{10}-Kallidin.

3. The antibody or antigen binding fragment thereof of any of the preceding claims that inhibits the binding of Kallidin or des-Arg_{10}-Kallidin to a bradykinin-1 receptor.

4. The antibody or antigen binding fragment thereof of any of the preceding claims that binds specifically to mouse Kallidin-like peptide (KLP).

5. The antibody or antigen binding fragment thereof of any of the preceding claims comprising a heavy chain variable domain comprising an HCDR3 amino acid sequence selected from the group consisting of:

a) SEQ ID NO: 7 [X_1Y X_2 X_3D X_4HAM X_5Y], wherein

X_1 is Y, F or H,

X_2 is R, D, A, V, L, I, M, F, Y or W,

X_3 is Y, F, W or H,

X_4 is D, E or Y, and,

X_5 is D or E;

b) SEQ ID NO: 63 [X_1EYDGX_2Y$X_3$$X_4LDX_5$], wherein

X_1 is W or F,

X_2 is N or no amino acid;

X_3 is Y or S,

X_4 is D or P, and

X_5 is F or Y;

c) SEQ ID NO: 13;

d) SEQ ID NO: 32;

e) SEQ ID NO: 40;

f) SEQ ID NO: 47; and

g) SEQ ID NO: 55.

6. The antibody or antigen binding fragment thereof of any of the preceding claims further comprising an HCDR2 amino acid sequence selected from the group consisting of:

a) SEQ ID NO: 8 [YFX$_1$PX$_2$NGNTGYNQKFRG], wherein

X$_1$ is D, R, A, V, L, I, M, F, Y or W, and

X$_2$ is Y, D, E, N, or Q;

b) SEQ ID NO: 64 [WX$_1$DPENGDX$_2$X$_3$YAPKFQG], wherein

X$_1$ is I, or V,

X$_2$ is T, or S, and

X$_3$ is G, or D;

c) SEQ ID NO: 14

d) SEQ ID NO: 33;

e) SEQ ID NO: 41;

f) SEQ ID NO: 48; and

g) SEQ ID NO: 56.

7. The antibody or antigen binding fragment thereof of any of the preceding claims further comprising an HCDR1 amino acid sequence selected from the group consisting of:

a) SEQ ID NO: 9 [GYSFTDYX$_1$IY], wherein X$_1$ is N, W or Y;

b) SEQ ID NO: 65 [GFNIKDYYX$_1$H], wherein X$_1$ is L, or M;

c) SEQ ID NO: 15;

d) SEQ ID NO: 34;

e) SEQ ID NO: 42;

f) SEQ ID NO: 49; and

g) SEQ ID NO: 57.

8. The antibody or antigen binding fragment thereof of any of the preceding claims further comprising a light chain variable domain comprising an LCDR3 amino acid sequence selected from the group consisting of:

a) SEQ ID NO: 10 [QQ X$_1$ X$_2$S X$_3$P X$_4$T], wherein

X$_1$ is Y, F or H,

X$_2$ is Y, F, H or W,

X$_3$ is Y, F, T or H, and,

X$_4$ is W, Y, F, H or L:

b) SEQ ID NO: 66 [QX$_1$X$_2$X$_3$SX$_4$PX$_5$T], wherein

X_1 is Q or N,
X_2 is Y, F, D or H,
X_3 is Y, F, H or W,
X_4 is Y, F, T or H, and
X_5 is W, Y, F, H or L;
c) SEQ ID NO: 69 [X_1QGTHFPYT], wherein X_1 is L or M;
d) SEQ ID NO: 16;
e) SEQ ID NO: 35;
f) SEQ ID NO: 43;
g) SEQ ID NO: 50; and
h) SEQ ID NO: 58.

9. The antibody or antigen binding fragment thereof of any of the preceding claims further comprising an LCDR2 amino acid sequence selected from the group consisting of:
a) SEQ ID NO: 11 [WASTRX_1], wherein X_1 is E, D, Q or N;
b) SEQ ID NO: 67 [X_1ASTRX_2], wherein
X_1 is W or G, and
X_2 is E, D, Q or N;
c) SEQ ID NO: 17;
d) SEQ ID NO: 36;
e) SEQ ID NO: 51; and
f) SEQ ID NO: 59.

10. The antibody or antigen binding fragment thereof of any of the preceding claims further comprising an LCDR1 amino acid sequence selected from the group consisting of:
a) SEQ ID NO: 12 [KSSQSLL X_1SSNQKN X_2LA], wherein
X_1 is W, H, Y or F, and
X_2 is H or Y;
b) SEQ ID NO: 68 [KSSQSLLX_1X_2SX_3QX_4NX_5LA], wherein
X_1 is W, H, Y or F,
X_2 is S or G,
X_3 is N or D,
X_4 is K or R,
X_5 is H or Y.
c) SEQ ID NO: 70 [KSSQSLLYSNGX_1TYLN],wherein X_1 is K or E;
b) SEQ ID NO: 18;
c) SEQ ID NO: 37;

d) SEQ ID NO: 44;
e) SEQ ID NO: 52; and
f) SEQ ID NO: 60.

11. The antibody or antigen binding fragment thereof of any one of claims 1-4 comprising a light chain variable domain comprising an LCDR3 amino acid sequence selected from the group consisting of:

a) SEQ ID NO: 10 [QQ X_1 X_2S X_3P X_4T], wherein
X_1 is Y, F or H,
X_2 is Y, F, H or W,
X_3 is Y, F, T or H, and,
X_4 is W, Y, F, H or L:
b) SEQ ID NO: 66 [Q$X_1$$X_2$$X_3SX_4PX_5$T], wherein
X_1 is Q or N,
X_2 is Y, F, D or H,
X_3 is Y, F, H or W,
X_4 is Y, F, T or H, and
X_5 is W, Y, F, H or L;
c) SEQ ID NO: 69 [X_1QGTHFPYT], wherein X_1 is L or M;
d) SEQ ID NO: 16;
e) SEQ ID NO: 35;
f) SEQ ID NO: 43;
g) SEQ ID NO: 50; and
h) SEQ ID NO: 58.

12. The antibody or antigen binding fragment thereof of claim 11 further comprising an LCDR2 amino acid sequence selected from the group consisting of:

a) SEQ ID NO: 11 [WASTRX_1], wherein X_1 is E, D, Q or N;
b) SEQ ID NO: 67 [X_1ASTRX_2], wherein
X_1 is W or G, and
X_2 is E, D, Q or N;
c) SEQ ID NO: 17;
d) SEQ ID NO: 36;
e) SEQ ID NO: 51; and
f) SEQ ID NO: 59.

13. The antibody or antigen binding fragment thereof of claim 12 further comprising an LCDR1 amino acid sequence selected from the group consisting of:

a) SEQ ID NO: 12 [KSSQSLL X_1SSNQKN X_2LA], wherein

X_1 is W, H, Y or F, and

X_2 is H or Y;

b) SEQ ID NO: 68 [KSSQSLL$X_1X_2SX_3QX_4NX_5$LA], wherein

X_1 is W, H, Y or F,

X_2 is S or G,

X_3 is N or D,

X_4 is K or R,

X_5 is H or Y.

c) SEQ ID NO: 70 [KSSQSLLYSNGX_1TYLN],wherein X_1 is K or E;

b) SEQ ID NO: 18;

c) SEQ ID NO: 37;

d) SEQ ID NO: 44;

e) SEQ ID NO: 52; and

f) SEQ ID NO: 60.

14. The antibody or antigen binding fragment thereof of any one of claims 1-4 comprising a heavy chain variable region comprising the HCDR3, HCDR2 and HCDR1 region amino sequences set forth in SEQ ID NOs 13, 14, and 15, respectively, and one or more amino acid substitution at positions selected from the group consisting of H1, H5, H9, H11, H12, H16, H38, H40, H41, H43, H44, H66, H75, H79, H81, H82A, H83, H87, and H108 according to Kabat.

15. The antibody or antigen binding fragment thereof of claim 14 further comprising a light chain variable region comprising the LCDR3, LCDR2 and LCDR1 region amino sequences set forth in SEQ ID NOs 16, 17, and 18, respectively, and one or more amino acid substitution at positions selected from the group consisting of L5, L9, L15, L18, L19, L21, L22, L43, L63, L78, L79, L83, L85, L100 and L104, according to Kabat.

16. The antibody or antigen binding fragment thereof of any one of claims 1-4 comprising a light chain variable region comprising the LCDR3, LCDR2 and LCDR1 region amino sequences set forth in SEQ ID NOs 16, 17, and 18, respectively, and one or more amino acid substitution at positions selected from the group consisting of L5, L9, L15, L18, L19, L21, L22, L43, L63, L78, L79, L83, L85, L100 and L104 according to Kabat.

17. The antibody or antigen binding fragment thereof of any one of claims 1-4 comprising a heavy chain variable region amino acid sequence with at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 20, 21, 22, 24, 25, 38, 45, 53, and 61.

18. The antibody or antigen binding fragment thereof of claim 17 further comprising a light chain variable domain amino acid sequence with at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 27, 28, 29, 29, 30, 31, 39, 46, 54, and 62.

19. The antibody or antigen binding fragment thereof of any one of claims 1-4 comprising a light chain variable region amino acid sequence with at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 27, 28, 29, 29, 30, 31, 39, 46, 54, and 62.

20. The antibody or antigen binding fragment thereof of any one of claims 1-4 comprising a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 19, 20, 21, 22, 24, 25, 38, 45, 53, and 61.

21. The antibody, or antigen binding fragment thereof, of claim 20, further comprising a light chain variable domain amino acid sequence selected from the group consisting of: SEQ ID NO: 26, 27, 28, 29, 29, 30, 31, 39, 46, 54, and 62.

22. The antibody or antigen binding fragment thereof of any one of claims 1-4 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 26, 27, 28, 29, 29, 30, 31, 39, 46, 54, and 62.

23. The antibody or antigen binding fragment thereof of any one of claims 1-4 comprising the heavy chain and light chain variable region amino acid sequences set forth in SEQ ID NO: 19 and 26, SEQ ID NO: 20 and 27, SEQ ID NO: 21 and 28; SEQ ID NO: 22 and 28; SEQ ID NO: 23 and 29; SEQ ID NO: 24 and 30; SEQ ID NO: 25 and 31; SEQ ID NO: 38 and 39, SEQ ID NO: 45 and 46, SEQ ID NO: 53 and 54, or SEQ ID NO: 61 and 62, respectively.

24. An antibody, or antigen binding fragment thereof, that specifically binds to Kallidin and des-Arg_{10}-Kallidin, wherein the antibody, or antigen binding fragment thereof, competes for binding to Kallidin and des-Arg_{10}-Kallidin with an antibody comprising the heavy chain and light chain variable region amino acid sequences set forth in SEQ ID NO: 19 and 26, SEQ ID NO: 38 and 39, SEQ ID NO: 45 and 46, SEQ ID NO: 53 and 54, or SEQ ID NO: 61 and 62, respectively.

25. An isolated monoclonal antibody or antigen binding fragment thereof that competes for binding to Kallidin or des-Arg_{10}-Kallidin with the antibody of any one of the preceding claims, and does not bind to Bradykinin or desArg_9-Bradykinin.

26. An isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to a conformational epitope of kallidin (KD) or desArg10-Kallidin (DAKD) which adopts a Pro4 kink conformation comprising a type II tight turn at Proline 4 of the KD or DAKD).

27. The antibody or antigen binding fragment of claim 26, wherein the Pro 4 kink conformation of KD or DAKD further comprises amino acid repeats of a sigmoid shape which align the hydrophobic side chains of the amino acids in a spatially stacking mode.

28. The antibody or antigen binding fragment of claim 26 or 27, which

(a) specifically binds Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin;

b) specifically binds to Kallidin or des-Arg_{10}-Kallidin with a KD of less than $1x10^{-10}$ M;

c) specifically binds to Kallidin or des-Arg_{10}-Kallidin with a K_{off} of less than $1x10^{4}$ s^{-1}; and/or

d) specifically binds to Kallidin or des-Arg_{10}-Kallidin and inhibits binding to the bradykinin B1 receptor.

29. An antibody of any one of the preceding claims conjugated to a diagnostic or therapeutic agent.

30. An isolated nucleic acid encoding the amino acid sequence of the antibody, or antigen binding fragment thereof, of any one of the preceding claims.

31. A recombinant expression vector comprising the nucleic acid of claim 30.

32. A host cell comprising the recombinant expression vector of claim 31.

33. A method of producing an antibody that binds specifically to Kallidin and des-Arg_{10}-Kallidin, comprising culturing the host cell of claim 32 under conditions such that an antibody that binds specifically to Kallidin and des-Arg_{10}-Kallidin is produced by the host cell.

34. A pharmaceutical composition comprising the antibody, or antigen binding fragment thereof, of any one of claims 1-28 and one or more pharmaceutically acceptable carrier.

35. A method for treating a Kallidin or des-Arg_{10}-Kallidin-associated disease or disorder, the method comprising administering to a subject in need of thereof the pharmaceutical composition of claim 34.

36. The method of claim 35, wherein the disease or disorder is chronic pain.

37. A method of generating an antibody that specifically binds to des-Arg_9- Bradykinin and des-Arg_{10}-Kallidin-like peptide comprising: immunizing an animal with an immunogen comprising a peptide, wherein the peptide consists of the amino acid sequence set forth in SEQ ID No.11, and wherein the amino terminal arginine of the peptide is indirectly coupled to a carrier moiety through a linker moiety, such that an antibody that specifically binds to des-Arg_9- Bradykinin, des-Arg_{10}-Kallidin and des-Arg_{10}-Kallidin-like peptide is produced by the immune system of the animal.

38. The method claim 37, further comprising isolating from the animal, the antibody, a nucleic isolating encoding the antibody, or an immune cell expressing the antibody.

39. The method claim 37, wherein the carrier moiety is a protein.

40. The method claim 39, wherein the protein is Keyhole limpet hemocyanin (KLH).

41. The method claim 40, wherein the linker moiety comprises [Gly-Gly-Gly]n, wherein n is at least 1.

We Claim:

1. An isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin, wherein the antibody or antigen binding fragment comprises:

i) a heavy chain variable domain comprising a heavy chain complementarity determining region 3 (HCDR3) amino acid sequence selected from the group consisting of:

a) SEQ ID NO: 7 [X_1Y X_2X_3D X_4HAM X_5Y], wherein

X_1 is Y, For H,

X_2 is R, D, A, V, L, I, M, F, Y or W,

X_3 is Y, F, W or H,

X_4 is D, E or Y, and,

X_5 is D or E;

b) SEQ ID NO: 63 [X_1EYDGX_2YX_3X_4LDX_5], wherein

X_1 is W or F,

X_2 is N or no amino acid;

X_3 is Y or S,

X_4 is D or P, and

X_5 is F or Y;

c) SEQ ID NO: 13;

d) SEQ ID NO: 32;

e) SEQ ID NO: 40;

f) SEQ ID NO: 47; and

g) SEQ ID NO: 55;

ii) a heavy chain variable domain comprising a heavy chain complementarity determining region 2 (HCDR2) amino acid sequence selected from the group consisting of:

h) SEQ ID NO: 8 [YFX_1PX_2NGNTGYNQKFRG], wherein

X_1 is D, R, A, V, L, I, M, F, Y or W, and

X_2 is Y, D, E, N, or Q;

i) SEQ ID NO: 64 [WX_1DPENGDX_2X_3YAPKFQG], wherein

X_1 is I, or V,

X_2 is T, or S, and

X_3 is G, or D;

j) SEQ ID NO: 14

k) SEQ ID NO: 33;

l) SEQ ID NO: 41;

m) SEQ ID NO: 48; and

n) SEQ ID NO: 56;

iii) a heavy chain variable domain comprising a heavy chain complementarity determining region 1 (HCDR1) amino acid sequence selected from the group consisting of:

o) SEQ ID NO: 9 [GYSFTDYX$_1$IY], wherein X_1 is N, W or Y;

p) SEQ ID NO: 65 [GFNIKDYYX$_1$H], wherein X_1 is L, or M;

q) SEQ ID NO: 15;

r) SEQ ID NO: 34;

s) SEQ ID NO: 42;

t) SEQ ID NO: 49; and

u) SEQ ID NO: 57;

iv) a light chain variable domain comprising a light chain complementarity determining region 3 (LCDR3) amino acid sequence selected from the group consisting of:

v) SEQ ID NO: 10 [QQ X_1 X_2S X_3P X_4T], wherein

X_1 is Y, For H,

X_2 is Y, F, H or W,

X_3 is Y, F, T or H, and,

X_4 is W, Y, F, H or L:

w) SEQ ID NO: 66 [QX$_1$X$_2$X$_3$SX$_4$PX$_5$T], wherein

X_1 is Q or N,

X_2 is Y, F, D or H,

X_3 is Y, F, H or W,

X_4 is Y, F, T or H, and

X_5 is W, Y, F, H or L;

x) SEQ ID NO: 69 [X$_1$QGTHFPYT], wherein X_1 is L or M;

z) SEQ ID NO: 16;

aa) SEQ ID NO: 35;

bb) SEQ ID NO: 43;

cc) SEQ ID NO: 50; and

dd) SEQ ID NO: 58;

v) a light chain variable domain comprising a light chain complementarity determining region 2 (LCDR21 amino acid sequence selected from the group consisting of:

ee) SEQ ID NO: 11 [WASTRX$_1$], wherein X_1 is E, D, Q or N;

ff) SEQ ID NO: 67 [X_1ASTRX_2], wherein
X_1 is W or G, and
X_2 is E, D, Q or N;
gg) SEQ ID NO: 17;
hh) SEQ ID NO: 36;
ii) SEQ ID NO: 51; and
jj) SEQ ID NO: 59;
and
vi) a light chain variable domain comprising a light chain complementarity determining region 1 (LCDR11 amino acid sequence selected from the group consisting of:
kk) SEQ ID NO: 12 [KSSQSLL X_1SSNQKN X_2LA], wherein
X_1 is W, H, Y or F, and
X_2 is H or Y;
ll) SEQ ID NO: 68 [KSSQSLLX_1X_2SX_3QX_4NX_5LA], wherein
X_1 is W, H, Y or F,
X_2 is S or G,
X_3 is N or D,
X_4 is K or R,
X_5 is H or Y,
mm) SEQ ID NO: 70 [KSSQSLLYSNGX_1TYLN], wherein X_1 is K or E;
nn) SEQ ID NO: 18;
oo) SEQ ID NO: 37;
pp) SEQ ID NO: 44;
qq) SEQ ID NO: 52; and
rr) SEQ ID NO: 60.

2. The isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin of claim 1, wherein the antibody or antigen binding fragment comprises:
a) a heavy chain variable domain comprising the consensus HCDR3, HCDR2 and HCDR1 region amino sequences set forth in SEQ ID Nos: 7, 8, and 9, respectively; and
b) a light chain variable domain comprising the LCDR3, LCDR2 and LCDR1 region amino sequences set forth in SEQ ID Nos: 10, 11, and 12, respectively.

3. The isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-

Bradykinin of claim 2, wherein the antibody or antigen binding fragment comprises:
a) a heavy chain variable domain comprising the HCDR3, HCDR2 and HCDR1 region amino sequences set forth in SEQ ID Nos: 13, 14, and 15, respectively; and
b) a light chain variable domain comprising the LCDR3, LCDR2 and LCDR1 region amino sequences set forth in SEQ ID Nos: 16, 17, and 18, respectively.

4. The isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin of claim 1, wherein the antibody or antigen binding fragment comprises:
a) a heavy chain variable domain comprising the HCDR3, HCDR2 and HCDR1 region amino sequences set forth in SEQ ID Nos: 32, 33, and 34, respectively; and
b) a light chain variable domain comprising the LCDR3, LCDR2 and LCDR1 region amino sequences set forth in SEQ ID Nos: 35, 36, and 37, respectively.

5. The isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin of claim 1, wherein the antibody or antigen binding fragment comprises:
a) a heavy chain variable domain comprising the HCDR3, HCDR2 and HCDR1 region amino sequences set forth in SEQ ID Nos: 40, 41 and 42, respectively; and
b) a light chain variable domain comprising the LCDR3, LCDR2 and LCDR1 region amino sequences set forth in SEQ ID Nos: 43, 17, and 44, respectively.

6. The isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin of claim 1, wherein the antibody or antigen binding fragment comprises:
a) a heavy chain variable domain comprising the HCDR3, HCDR2 and HCDR1 region amino sequences set forth in SEQ ID Nos: 47, 48, and 49, respectively; and
b) a light chain variable domain comprising the LCDR3, LCDR2 and LCDR1 region amino sequences set forth in SEQ ID Nos: 50, 51, and 52, respectively.

7. The isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin of claim 1, wherein the antibody or antigen binding fragment comprises:
a) a heavy chain variable domain comprising the HCDR3, HCDR2 and HCDR1 region amino sequences set forth in SEQ ID Nos: 55, 56, and 57, respectively; and
b) a light chain variable domain comprising the LCDR3, LCDR2 and LCDR1 region

amino sequences set forth in SEQ ID Nos: 58, 59, and 60, respectively.

8. A pharmaceutical composition comprising the antibody, or antigen binding fragment thereof, of claim 1 and one or more pharmaceutically acceptable carrier(s).

9. An isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin, wherein the antibody or antigen binding fragment comprises thereof of claim 1 comprising:

a) a heavy chain variable domain comprising the HCDR3, HCDR2 and HCDR1 region amino sequences set forth in SEQ ID Nos: 13, 14, and 15, respectively, and one or more amino acid substitution at positions selected from the group consisting of H1, H5, H9, H11, H12, H16, H38, H40, H41, H43, H44, H66, H75, H79, H81, H82A, H83, H87, and H108, according to Kabat; and

b) a light chain variable domain comprising the LCDR3, LCDR2 and LCDR1 region amino sequences set forth in SEQ ID Nos: 16, 17, and 18, respectively, and one or more amino acid substitution at positions selected from the group consisting of L5, L9, L15, L18, L19, L21, L22, L43, L63, L78, L79, L83, L85, L100 and L104, according to Kabat.

10. A pharmaceutical composition comprising the antibody, or antigen binding fragment thereof, of claim 9 and one or more pharmaceutically acceptable carrier(s).

11. An isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin, wherein the antibody or antigen binding fragment thereof comprises the heavy chain and light chain variable domain amino acid sequences set forth in SEQ ID NO: 24 and 30, respectively.

12. An isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin, wherein the antibody or antigen binding fragment comprises:

a) a heavy chain variable region domain amino acid sequence with at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 20, 21, 22, 24, 25, 38, 45, 53, and 61; and

b) a light chain variable domain amino acid sequence with at least 90% identity to an

amino acid sequence selected from the group consisting of SEQ ID NOs: 26, 27, 28, 29, 30, 31, 39, 46, 54, and 62.

13. An isolated monoclonal antibody or antigen binding fragment thereof that specifically binds to Kallidin or des-Arg_{10}-Kallidin but not to Bradykinin or des-Arg_9-Bradykinin, wherein the antibody or antigen binding fragment comprises:
a) a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 19, 20, 21, 22, 24, 25, 38, 45, 53, and 61; and
b) a light chain variable domain amino acid sequence selected from the group consisting of: SEQ ID NO: 26, 27, 28, 29, 30, 31, 39, 46, 54, and 62.